Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results tags : Disease save search
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | $42.15 0.02% 0.02% 810K
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.73%
H: 2.49%
C: 0.11%
abrysvo disease positive risk for rsv results study
BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
BWAY | $4.835 0.94% 0.93% 41K
|
Health Technology
|
| O: 6.79%
H: 0.0%
C: -7.9%
disease parkinson's review treat potential results
Study on Foot-and-Mouth Disease Virus Results in Submission for Additional EPA Label
Published: 2024-03-11 (Crawled : 14:00) - globenewswire.com
TOMZ | $0.5801 8.18% 9.5K
|
Producer Manufacturing
|
| O: -0.01%
H: 1.37%
C: -1.64%
label disease virus results study submission
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Published: 2024-02-28 (Crawled : 12:30) - prnewswire.com
PTN | $1.84 -2.65% 0.05% 150K
|
Health Technology
|
| O: -44.58%
H: 25.45%
C: 11.36%
pl9643 disease eye trial results
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Published: 2024-02-26 (Crawled : 07:00) - globenewswire.com
ZEAL | News | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
pharma liver disease fibrosis trial results
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
Published: 2024-02-24 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
disease urticaria results
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
TARS | $32.405 -1.36% -1.37% 630K
|
Health Technology
|
| O: -0.43%
H: 6.07%
C: 5.13%
tp-05 disease positive topline trial results
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
Published: 2024-01-24 (Crawled : 14:00) - globenewswire.com
SILO | $1.97 0.0% 40K
|
Finance and Insurance
|
| O: 10.0%
H: 5.19%
C: -3.9%
pharma disease alzheimer’s positive results study
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
Published: 2024-01-11 (Crawled : 21:00) - globenewswire.com
XOMA | News | $24.97 1.55% 1.52% 17K
|
Health Technology
|
| O: 1.16%
H: 0.0%
C: -4.0%
fda disease million payment results milestone
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
Published: 2024-01-08 (Crawled : 18:00) - biospace.com/
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -0.03%
H: 0.67%
C: 0.32%
VCYT | $19.43 1.2% 1.18% 1.4M
|
Health Technology
|
| O: 2.53%
H: 10.54%
C: 10.31%
disease genomics acquisition diagnostics platform
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Published: 2024-01-05 (Crawled : 11:00) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.0%
H: 4.59%
C: 3.72%
TBPH | $9.35 1.63% 1.6% 430K
|
Health Technology
|
| O: -11.02%
H: 6.05%
C: 1.17%
yupelri disease biopharma results study
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Published: 2023-12-20 (Crawled : 22:00) - globenewswire.com
ROIV | $10.46 0.97% 0.96% 4.7M
|
Manufacturing
|
| O: 4.52%
H: 2.02%
C: 1.25%
IMVT S | $28.24 -0.28% -0.28% 1.1M
|
Health Technology
|
| O: 11.69%
H: 0.64%
C: -3.24%
disease positive results
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Published: 2023-12-20 (Crawled : 22:00) - globenewswire.com
IMVT S | $28.24 -0.28% -0.28% 1.1M
|
Health Technology
|
| O: 11.69%
H: 0.64%
C: -3.24%
disease positive results
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease
Published: 2023-12-20 (Crawled : 13:00) - globenewswire.com
LGVN 1 d | $1.93 -3.98% -4.15% 460K
|
|
| O: 6.15%
H: 2.89%
C: -21.74%
disease biomarker alzheimer’s positive treatment trial imaging results
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease
Published: 2023-12-18 (Crawled : 21:00) - globenewswire.com
SGHT | $5.14 -1.91% -1.95% 130K
|
|
| O: -0.3%
H: 8.84%
C: 2.44%
tearcare disease publication treatment sciences eye trial results
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
Published: 2023-12-12 (Crawled : 12:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K
|
Health Technology
|
| O: -2.93%
H: 10.55%
C: 6.53%
fosgonimeton pharma disease parkinson's treatment dementia trial results
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
Published: 2023-12-11 (Crawled : 13:00) - globenewswire.com
TARS | $32.405 -1.36% -1.37% 630K
|
Health Technology
|
| O: 0.64%
H: 2.59%
C: 2.24%
tp-03 disease positive treatment topline trial results
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
Published: 2023-12-10 (Crawled : 00:20) - globenewswire.com
AGIO | $29.52 0.31% 0.3% 750K
|
Health Technology
| Email alert
Add to watchlist
disease positive cell meeting results study
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.